BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS)a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncology and non-oncology conditions, announces the sale of its Sculpturaâ¢ assets to Empyrean Medical Systems for $15 million in cash. The sale, which closed on February 25, 2022, included inventory from Sculpturaâ¢ systems and parts, plus any related intellectual property.
âSculptura will be in excellent, capable hands under Empyrean’s leadership, and we wish them the best in their endeavors with this fabulous technology,â said Joe Sardano, President and CEO of Sensus Healthcare. “Given the rebound in sales of Sensus’ SRT systems and the dermatology market as a whole, we believe our resources are better focused on our core dermatology business. Sensus has already begun to expand its dermatology product offering, with the recent additions of the TransDermiqueâ¢ Non-Invasive Infusion Drug Delivery System, as well as Sensus Laser Systems, and we intend to use the proceeds from this sale to grow even further. In addition, we plan to seek Board approval to use a portion of the proceeds from the purchase of Sensus common stock; however, no decision has been made on this. If the Board approves a buyback program, we will make an appropriate announcement at that time.”
“We are excited to acquire and add Sculpturaâ¢ to Empyrean’s arsenal of cancer products and solutions,” said Kal Fishman, president and CEO of Empyrean Medical Systems. “This is a natural continuum of Sensus’ suite of patient-centric innovations and solutions that will allow us to bring this disruptive technology to patients and clinicians around the world. We are excited to launch Sculptura â¢ under the Empyrean’s Morpheusâ¢ brand, which will provide clinicians with a state-of-the-art robot-assisted Beam Sculptingâ¢ treatment modality for their cancer patients worldwide.Empyrean’s mission is to innovate and provide breakthrough treatment technologies for our patients and the launch of Morpheusâ¢ this year is our first act on this journey.”
The Sculpturaâ¢ system provides targeted directional anisotropic radiation therapy (ARTâ¢) and brachytherapy using proprietary, state-of-the-art 3D beam sculptingâ¢ to treat patients undergoing cancer treatment during surgery or at the tumor site quickly and effectively. Sculptura received 510(k) clearance from the United States Food and Drug Administration in February 2019.
About Sensus Health
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive, and cost-effective treatments for oncology and non-oncology conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of over a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100â¢, SRT-100+â¢ and SRT-100 Visionâ¢ Systems. With its portfolio of innovative medical devices, Sensus offers breakthrough treatment options to improve the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
About Empyrean Medical Systems
Empyrean Medical Systems is an innovator and paradigm shifter in radiation oncology. Empyrean aims to fundamentally change the way cancer patients are treated around the world while improving and improving clinical outcomes and quality of life for every patient. As a cutting-edge innovator, Empyrean aims to disrupt the fields of oncology and radiation oncology through the introduction of cutting-edge medical devices, artificial intelligence analytical solutions, clinical applications and genomic therapeutic agents. Empyrean’s multimodal solutions deliver personalized and efficient healthcare, improving clinical productivity and improving outcomes for patients, providers, healthcare systems and researchers worldwide.
For more information, visit www.empyreanmed.com.
This press release contains statements about Sensus that are or may be deemed to be “forward-looking statements”. In some cases, these statements can be identified by the use of forward-looking terminology such as “believes”, “estimates”, “plans”, “expects”, “plans”, “intends”. , “may”, “could”, “could”, “will”, “should”, “approximately”, “potential” or negative or other variations of these terms or comparable terminology, although not all forward-looking statements not contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments and circumstances relating to Sensus, its industry and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timeframes. or to a greater or lesser degree than expected. Although Sensus believes it has a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, or actual results of operations, financial condition and liquidity, or the development of the industry in which Sensus operates may differ materially from the forward-looking statements contained in this press release, due to, among other things, the following factors: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; Sensus’ ability to achieve profitability; its ability to obtain and retain the intellectual property necessary to adequately protect its products, and its ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third-party payer reimbursement for clinical procedures using Sensus’ products, and the willingness of healthcare providers to purchase its products if the level of reimbursement decreases; regulatory requirements applicable to Sensus and its competitors; its ability to effectively manage its manufacturing processes and costs; risks arising from its international operations; laws, regulations or other government action affecting Sensus’ products, taxes, international trade regulations or other aspects of its business; the concentration of its customers in the United States and China, including the concentration of sales to a particular customer in the United States; and other risks described from time to time in Sensus’ filings with the Securities and Exchange Commission, including its annual report on Form 10-K and quarterly reports on Form 10-Q.
Furthermore, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. All forward-looking statements contained in this press release speak only as of the date of this statement, and Sensus undertakes no obligation to update such statements to reflect events or circumstances after the date of this press release. , except as required by applicable law. You should carefully read the “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of Sensus’ periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in his activity.
Seal of Madelyn
Image 1: Empyrean medical systems
This content was posted through the press release distribution service on Newswire.com.